Finch Therapeutics' IPO Lock-up Period Ends On Sep. 15

finch sep13 lt

The lockup period of Somerville, Massachusetts-based Finch Therapeutics Group (FNCH) expires on September 15.

Founded in 2014, Finch Therapeutics is a clinical-stage microbiome therapeutics company developing drugs for gastrointestinal diseases, such as recurrent Clostridioides difficile infection (CDI), inflammatory bowel disease, ulcerative colitis (UC) and Crohn's disease (CD).

The lead candidate CP101 has successfully completed a phase II trial in recurrent C. difficile Infection, dubbed PRISM3.

A phase III trial which is designed to serve as the second pivotal trial of CP101 for recurrent C. difficile infection, dubbed PRISM4, is expected to be initiated this year.

An open-label safety study of CP101 for recurrent CDI, dubbed PRISM-EXT, is underway, with results expected in the second half of 2021.

CP101 is also being explored as a potential treatment for chronic Hepatitis B virus, and a phase Ib trial is this indication is expected to be initiated in early 2022.

Also in the pipeline are TAK-524, FIN-525, and FIN-211.

-- TAK-524, for the treatment of ulcerative colitis, is being developed under a global collaboration agreement between Takeda and Finch Therapeutics. This compound is expected to enter into phase I trials in the first half of 2022.

-- FIN-525, for the treatment of Crohn's disease, is in preclinical development. This compound is also being developed in partnership with Takeda.

-- FIN-211, an oral microbiome drug, is expected to advance into a phase Ib trial in the second half of this year.

Finch Therapeutics made its debut on the Nasdaq Global Select Market on March 19, 2021, offering its shares at a price of $17 each and as mentioned above, the 180 day lockup period expires on September 15.

FNCH opened the first day of trading on March 19 at $20.45 and closed at $21.32 that day. The stock has thus far hit a low of $11.56 and a high of $22.50.

FNCH closed Monday's trading at $13.46, up 0.45%.

For comments and feedback contact: editorial@rttnews.com

Follow RTT